Neurology/CNS Phase 2 Deal Benchmarks (2026)
Median upfront of $232M with total deal values reaching $2.7B.
Median Upfront
$232M
Total Deal Value
$2.0B
Royalty Range
10.8%–17.3%
Territory Multiplier
1x
Understanding Neurology/CNS Deal Benchmarks at Phase 2
Phase 2 Neurology/CNS licensing deals command a median upfront payment of $232M, with values ranging from $118M at the low end to $345M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.2B to $2.7B, with a median of $2.0B. Royalty rates for neurology/cns assets at this stage typically fall between 10.8% and 17.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $118M | $232M | $345M |
| Total Deal Value | $1.2B | $2.0B | $2.7B |
| Royalty Rate | 10.8% | — | 17.3% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Takeda | Lundbeck | $100M | $800M | licensing |
| 2022 | Biohaven Pharmaceutical | Pfizer | $11.6B | $11.6B | acquisition |
| 2020 | GW Pharmaceuticals | Jazz Pharmaceuticals | $7.2B | $7.2B | acquisition |
| 2022 | Voyager Therapeutics | Neurocrine Biosciences | $165M | $1.7B | licensing |
| 2021 | Biohaven Pharmaceutical | Pfizer | $500M | $1.2B | licensing |
| 2015 | Merck | Allergan | $250M | $250M | licensing |
| 2019 | Alder BioPharmaceuticals | Lundbeck | $1.9B | $1.9B | acquisition |
| 2017 | Amgen | Novartis | $0M | $400M | codevelopment |
| 2017 | CoLucid Pharmaceuticals | Eli Lilly | $960M | $960M | acquisition |
| 2017 | Teva | Otsuka | $50M | $65M | licensing |
See All Comparable Deals
View 10 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 2 Neurology/CNS deals?
How does Global territory affect Neurology/CNS deal value?
What royalty rates are typical for Phase 2 Neurology/CNS licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$32M upfront
Neurology/CNS · Preclinical · Global
$76M upfront
Neurology/CNS · Phase 1 · Global
$515M upfront
Neurology/CNS · Phase 3 · Global
$1.5B upfront
Neurology/CNS · Approved · Global
$258M upfront
Oncology · Phase 2 · Global
$547M upfront
Immunology · Phase 2 · Global
$589M upfront
Metabolic/Obesity · Phase 2 · Global
$128M upfront
Neurology/CNS · Phase 2 · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Neurology/CNS Phase 2 Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/neurology-phase-2-deals-global
<a href="https://solidus.ambrosiaventures.co/data/neurology-phase-2-deals-global">Neurology/CNS Phase 2 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=neurology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.